Autonomix Medical (AMIX) Q2 2026 earnings summary

Executive summary

• Development-stage medical device company focused on a catheter-based platform for sensing and treating nervous system disorders, with initial applications in pancreatic cancer pain and broader potential in chronic pain and cardiovascular disease.

• Completed first-in-human proof-of-concept study with positive outcomes; expanded clinical studies to additional cancer pain indications.

• Strengthened intellectual property with new U.S. and European patents and presented early results at major medical conferences.

Financial highlights

• No revenue for the three and six months ended September 30, 2025 and 2024.

• Net loss of $7.5 million for the quarter and $10.8 million for the six months ended September 30, 2025, compared to $2.8 million and $5.5 million for the same periods in 2024.

• Operating expenses increased 166% year-over-year for the quarter, driven by higher R&D and G&A costs, especially stock-based compensation from option cancellations.

• Cash used in operating activities was $6.4 million for the six months ended September 30, 2025.

• Cash and cash equivalents were $7.5 million as of September 30, 2025.

Outlook and guidance

• Current cash resources are expected to fund operations into, but not beyond, Q3 2026.

• Additional financing of $30–36 million estimated to be required to reach commercialization.

• Plans to continue increasing R&D spending as clinical trials and product development progress.